Table 1. Clinicopathological characteristics of study versus Z0011 population.
| Parameters | Z0011 study intention to treat (n = 856) | Present study (n = 128) | Χ2 | p |
|---|---|---|---|---|
| Age, years | ||||
| ≤50, no. (%) | 295 (35.2) | 62 (48.4) | 7.84 | 0.005 |
| >50, no. (%) | 544 (64.8) | 66 (51.6) | ||
| Clinical T stage, no. (%) | ||||
| T1 | 587 (69.3) | 22 (17.2) | 126.8 | <0.001 |
| T2 | 260 (30.7) | 106 (82.8) | ||
| Estrogen receptor, no. (%) | ||||
| ER+ | 659 (83) | 108 (84.4) | 0.14 | 0.69, ns |
| ER− | 135 (17) | 20 (15.6) | ||
| Progesterone receptor, no. (%) | ||||
| PR+ | 534 (68.8) | 105 (82) | 9.2 | 0.003 |
| PR− | 242 (31.2) | 23 (18) | ||
| Modified Bloom-Richardson score, no (%) | ||||
| Grade 1 | 152 (23.8) | 9 (7) | 31.7 | <0.001 |
| Grade 2 | 306 (47.9) | 54 (42.2) | ||
| Grade 3 | 181 (28.3) | 65 (50.8) | ||
| Tumor type, no. (%) | ||||
| Infiltrating ductal | 700 (80.3) | 120 (93.8) | 9.7 | <0.001 |
| Infiltrating lobular | 63 (7.5) | 5 (3.9) | ||
| Others | 77 (9.2) | 3 (2.3) | ||
| Size of SLN mets, no. (%) | ||||
| Micrometastasis | 301 (41.2) | 22 (17.2) | 25.7 | <0.001 |
| Macrometastasis | 430 (58.8) | 106 (82.8) | ||
| Parameters | Z0011 ALND arm, intention to treat (n = 420) | Present study (n = 128) | X 2 | p |
| Completion ALND, no. (%) | ||||
| Non SLN positive | 97 (27) | 62 (48.4) | 18.04 | <0.001 |
| Non SLN negative | 258 (73) | 66 (51.6) |
ER = Estrogen receptor, PR = Progesterone receptor, ALND = Axillary lymph node dissection, SLN = Sentinel lymph node